What are the pertinent laboratory findings for osteoporosis in a 49-year-old male?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 6, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

For a 49-year-old male with suspected osteoporosis, bone mineral density testing with DXA is the gold standard for diagnosis, and laboratory tests such as comprehensive metabolic panel, complete blood count, 25-hydroxyvitamin D level, testosterone level, thyroid-stimulating hormone, parathyroid hormone, and 24-hour urinary calcium should be performed to identify secondary causes of osteoporosis 1.

Key Laboratory Tests

  • Comprehensive metabolic panel (CMP) to evaluate kidney and liver function, calcium, and phosphorus levels
  • Complete blood count (CBC) to rule out underlying hematologic disorders
  • 25-hydroxyvitamin D level to assess for vitamin D deficiency, which contributes to bone loss
  • Testosterone level to check for hypogonadism, a common cause of male osteoporosis
  • Thyroid-stimulating hormone (TSH) to rule out hyperthyroidism
  • Parathyroid hormone (PTH) and 24-hour urinary calcium to identify hyperparathyroidism or renal calcium wasting

Additional Tests to Consider

  • Serum protein electrophoresis to rule out multiple myeloma
  • Celiac disease antibodies if malabsorption is suspected
  • Specific tests for conditions like Cushing's syndrome if clinically indicated

Importance of DXA Testing

DXA testing is essential for diagnosing osteoporosis in men, as it measures bone mineral density and can help identify individuals at increased risk for fractures 1.

Risk Factors for Osteoporosis

Risk factors for osteoporotic fracture include increasing age, low body weight, history of parental hip fracture, ethnic background, previous clinical or morphometric vertebral fracture, and long-term use of certain medications such as glucocorticoids and anticoagulants 1.

Treatment Options

Pharmacologic treatments for osteoporosis include bisphosphonates, peptide hormones, estrogen, selective estrogen receptor modulators, and denosumab, which aim to prevent bone resorption and reduce the risk of fractures 1.

From the FDA Drug Label

The FDA drug label does not answer the question.

From the Research

Osteoporosis in Male 49 yo: Pertinent Labs

  • The following laboratory investigations are relevant for osteoporosis in a 49-year-old male:
    • Serum calcium
    • Phosphate
    • Creatinine
    • Alkaline phosphatase
    • 25-hydroxyvitamin D
    • Testosterone (specifically in men) 2
  • Parathyroid hormone (PTH) is measured in patients with abnormal serum calcium to determine its cause 2
  • Other laboratory investigations such as thyroid function testing, screening for multiple myeloma, and screening for Cushing's syndrome, are performed if indicated 2

Bone Turnover Markers and Fracture Risk

  • Measurement of bone turnover markers (BTMs) is currently not included in algorithms for fracture risk calculations due to the lack of data 2
  • However, BTMs may be useful for monitoring osteoporosis treatment 2
  • Further studies of the reference BTMs serum carboxy terminal telopeptide of collagen type I (s-CTX) and serum procollagen type I N-terminal propeptide (s-PINP) in fracture risk prediction and in monitoring various treatments for osteoporosis may help expedite their inclusion in routine clinical practice 2

Treatment and Management

  • Fracture risk algorithms that combine clinical risk factors and bone mineral density are now widely used in clinical practice to target high-risk individuals for treatment 3
  • The benefit versus risk profile is likely to be favourable for up to 10 years of treatment with bisphosphonates or denosumab in individuals at high risk of fracture 3
  • Therapy with teriparatide or abaloparatide should be considered in people at a very high or imminent risk of fracture, although treatment duration with these drugs is restricted to 18-24 months 3

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Osteoporosis.

Lancet (London, England), 2019

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.